EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

Georgina V Long, F Stephen Hodi, Evan J Lipson, Dirk Schadendorf, Paolo A Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J Gogas, Christopher D Lao, Juliana Janoski De Menezes und 8 weitere

NEJM Evidence · 28.03.2023 · 2 (4)

DOI: 10.1056/evidoa2200239 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 28.03.2023. Verfasst von Georgina V Long und 19 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsAntibodies, Monoclonal, HumanizedHumansNivolumabIpilimumabAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind Method

Substanzen

NivolumabrelatlimabIpilimumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney.
  • Dana-Farber Cancer Institute, Boston.
  • Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore.
  • Department of Dermatology, University Hospital Essen, Essen, Germany.
  • German Cancer Consortium, Partner Site Essen, Essen, Germany.
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.

Zitieren

APA

Long, G. V., Stephen Hodi, F., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Salman, P., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., Janoski De Menezes, J., Dalle, S., Arance, A., Grob, J. J., Keidel, S., Shaikh, A., Sobiesk, A. M., Dolfi, S., & Tawbi, H. A. (2023). Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evidence, 2(4). https://doi.org/10.1056/evidoa2200239

Vancouver

Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evidence. 2023;2(4). doi:10.1056/evidoa2200239

BibTeX
@article{Long2023,
  author = {Long, Georgina V and Stephen Hodi, F and Lipson, Evan J and Schadendorf, Dirk and Ascierto, Paolo A and Matamala, Luis and Salman, Pamela and Castillo Gutiérrez, Erika and Rutkowski, Piotr and Gogas, Helen J and Lao, Christopher D and Janoski De Menezes, Juliana and Dalle, Stéphane and Arance, Ana and Grob, Jean-Jacques and Keidel, Sarah and Shaikh, Anadil and Sobiesk, Anne Marie and Dolfi, Sonia and Tawbi, Hussein A},
  title = {Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma},
  journal = {NEJM Evidence},
  year = {2023},
  volume = {2},
  number = {4},
  doi = {10.1056/evidoa2200239}
}
Kostenlos starten →